At the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, researchers showed that MK-6482 induced clinical responses among patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma (RCC).
Eric Jonasch, MD, professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center, spoke to CancerNetwork about next steps for those with von Hippel-Lindau disease–associated renal cell carcinoma being treated with the HIF-2a Inhibitor, MK-6482.
Transcription:
The hope here is that this agent be approved and that in individuals who do have lesions that are starting to get to a size where they might need some type of intervention that they could get this drug instead of a surgical intervention and that they could be on this for some period of time. That would either delay or prevent the need for that surgical…